©The Author(s) 2021.
World J Gastrointest Oncol. Oct 15, 2021; 13(10): 1229-1243
Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1229
Published online Oct 15, 2021. doi: 10.4251/wjgo.v13.i10.1229
Table 1 Small molecules able to induce autophagic activity
| Agents | Mechanism of action |
| GDC-0941 | Inhibitor of class I PI3K |
| GDC-0980 | Dual inhibitor of PI3K and mTORC1 |
| Everolimus | mTORC1 inhibitor |
| Temsirolimus | mTORC1 inhibitor |
| Rapamycin | mTORC1 inhibitor |
| Tat–beclin 1 peptide | Releases beclin-1 into cytoplasm-regulate autophagosome formation |
| Metformin | AMPK activator |
| Fluspirilene | Antagonists of L-type Ca2+ channels |
| Loperamide | Antagonists of L-type Ca2+ channels |
| Amiodarone | Antagonists of L-type Ca2+ channels |
| Isoliensinine | Natural alkaloid |
| Cepharanthine | Natural alkaloid |
- Citation: Koustas E, Trifylli EM, Sarantis P, Papavassiliou AG, Karamouzis MV. Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. World J Gastrointest Oncol 2021; 13(10): 1229-1243
- URL: https://www.wjgnet.com/1948-5204/full/v13/i10/1229.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i10.1229